SNIPR BIOME
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target and kill bacteria with specific DNA sequences.
SNIPR BIOME
Social Links:
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.sniprbiome.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
60.2 M USD
Technology used in webpage:
Viewport Meta Google Font API LetsEncrypt Content Delivery Network Euro Cloudflare JS CDN JS YouTube Typekit LocalBusiness Schema
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - SNIPR Biome
North-East Family Office
North-East Family Office investment in Series A - SNIPR Biome
Life Sciences Partners
Life Sciences Partners investment in Series A - SNIPR Biome
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series A - SNIPR Biome
Wellington Partners
Wellington Partners investment in Series A - SNIPR Biome
Official Site Inspections
http://www.sniprbiome.com Semrush global rank: 9.35 M Semrush visits lastest month: 169
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "SNIPR Biome"
SNIPR Biome - Crunchbase Company Profile & Funding
Contact Email [email protected] SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses …See details»
SNIPR BIOME — Team
SNIPR, SNIPR BIOME, SNIPRBIOME, CRISPR GUIDED VECTOR, CGV, PICOBIOTICS, CRISPRBIOME and CRISPRBIOTICS are registered trademarks. Menu. Technology …See details»
SNIPR Biome - A CRISPR Company - LinkedIn
SNIPR Biome - A CRISPR Company Biotechnology Research Copenhagen, Capital Region 7,528 followers Clinical CRISPR and Gene Therapy of the Microbiome CompanySee details»
SNIPR BIOME — Our Approach and Technology
Therapeutic applications of our CRISPR editing technology. Therapeutic applications of our proprietary CRISPR editing technology include highly selective and programable bacterial …See details»
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
Apr 20, 2022 Christian Grøndahl, Dr.Med, Co-founder & CEO E-mail: [email protected] Mobile: +45 20202747 www.sniprbiome.com. Please follow us on LinkedIn & Twitter: …See details»
SNIPR Biome receives funding for the development of CRISPR …
Jun 28, 2024 SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform to improve …See details»
SNIPR Biome receives funding from CARB-X to support …
Apr 22, 2024 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will …See details»
SNIPR Biome Launches A Non-Profit Patent Licensing Program
Oct 3, 2022 E-mail: [email protected] Mobile: +45 20202747. Dr. Eric van der Helm, Head of Scientific Affairs E-mail: [email protected] Mobile: +45 24653162. www.sniprbiome.comSee details»
SNIPR Biome receives funding for the development of CRISPR …
Jun 28, 2024 SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform to improve …See details»
CARB-X is funding SNIPR BIOME to develop a CRISPR-engineered …
May 27, 2021 [email protected] About CARB-X Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to …See details»
Pipeline - SNIPR BIOME
[email protected]. SNIPR, SNIPR BIOME, SNIPRBIOME, CRISPR GUIDED VECTOR, CGV, PICOBIOTICS, CRISPRBIOME and CRISPRBIOTICS are registered trademarks. Menu. …See details»
SNIPR Biome reports positive clinical interim results for ... - BioSpace
May 31, 2023 E-mail: [email protected] Mobile: +45 20202747 www.sniprbiome.com Please follow us on LinkedIn & Twitter: @sniprbiome. Consilium Strategic Communications Tracy …See details»
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
Apr 22, 2011 The study plans to enroll 36 healthy volunteers for multiple ascending dosing of SNIPR001 (NCT05277350). SNIPR001 has been granted Fast-Track designation by the FDA …See details»
SNIPR Biome receives funding from CARB-X for advancement of …
Apr 22, 2024 About SNIPR001 SNIPR001, a CRISPR-armed phage therapeutic that specifically targets E. coli in the gut, is designed to prevent infections from spreading into the bloodstream …See details»
SNIPR Biome reports positive clinical interim results for ...
May 31, 2023 www.sniprbiome.com Please follow us on LinkedIn & Twitter: @sniprbiome. Consilium Strategic Communications Tracy Cheung, Chris Welsh, Davide Salvi Tel: +44 (0) …See details»
News & Press - SNIPR BIOME
SNIPR Biome receives USD 5.48 million funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials / 04.24. The 1b/2a trial will evaluate SNIPR001 …See details»
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
Apr 20, 2022 SNIPR001 has been granted Fast-Track designation by the FDA and is being developed in collaboration with the US non-profit organization CARB-X. With the initiation of …See details»
SNIPR Biome reports positive clinical interim results for ...
May 31, 2023 E-mail: [email protected] Mobile: +45 20202747 www.sniprbiome.com Please follow us on LinkedIn & Twitter: @sniprbiome. Consilium Strategic Communications Tracy …See details»
Publications - SNIPR BIOME
Addressing the Research and Development Gaps in Modern Phage Therapy / 03.24. We review the current state of phage therapy research, including major operational, epistemic, and …See details»